Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Study Phase : Preclinical
Recipient : Lipidor AB
Deal Size : $0.4 million
Deal Type : Expanded Collaboration
Details : Based on new IP (intellectual property), the scope of the collaboration agreement has expanded to include a new patent family covering innovative new AKVANO® topical formulations.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 29, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Recipient : Lipidor AB
Deal Size : $0.4 million
Deal Type : Expanded Collaboration
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Recipient : Lipidor AB
Deal Size : $0.4 million
Deal Type : Licensing Agreement
Details : Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 18, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Recipient : Lipidor AB
Deal Size : $0.4 million
Deal Type : Licensing Agreement
Reset All
